Reprogramming endothelial and vascular smooth muscle cells to prevent and treat hypertension.
Cellular reprogramming
Endothelial to mesenchymal transition
Hypertension
Oct4-Sox2-Klf4 transcription factors
Journal
Medical hypotheses
ISSN: 1532-2777
Titre abrégé: Med Hypotheses
Pays: United States
ID NLM: 7505668
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
pmc-release:
01
10
2024
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
ppublish
Résumé
The major pathophysiological characteristic of hypertension is the occurrence of small artery remodeling and endothelial dysfunction. There is also solid evidence showing that microcirculation abnormalities occur prior to the onset of hypertension. However, the mechanism(s) that trigger these changes prior to the elevation of blood pressure are unknown, and this may limit our ability to identify the cause of this disease and effectively treat it. In hypertension, as with aging, the vasculature becomes less susceptible to repair. One of the reasons is because endothelial cells start to deteriorate and present with exacerbated endothelial-to-mesenchymal transition (EndMT). Likewise, vascular smooth muscle cells (VSMC) also dedifferentiate into a synthetic phenotype, whereby they start to produce and secrete extracellular vesicles with a high migration and proliferation capacity for repairing vascular injury. Uncontrolled EndMT and/or VSMC phenotype switching contributes to vascular diseases, but the initial trigger for these conditions is unidentified. Importantly, EndMT and synthetic VSMC exhibit plasticity and can return to adopt an endothelial cell-like fate and present contractile phenotype again, respectively. Therefore, in this hypothesis we will take advantage of this plasticity, and we propose to manipulate this fate by inducing partial cellular reprogramming without passing through the pluripotent state. Specifically, we suggest that activation of the three master transcription factors, Oct-4, Sox-2, and Klf-4 (collectively termed OSK) will reprogram endothelial cells and prevent and reduce EndMT and VSMC synthetic phenotype. It was recently shown that activation of OSK was able to restore lost vision in old mice, and cancer risk was reduced by excluding c-Myc. Therefore, OSK treatment could provide new possibilities for vascular rejuvenation and treatment of hypertension.
Identifiants
pubmed: 37744557
doi: 10.1016/j.mehy.2023.111162
pmc: PMC10512690
mid: NIHMS1930787
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL149762
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103641
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR073172
Pays : United States
Organisme : NHLBI NIH HHS
ID : R00 HL151889
Pays : United States
Organisme : NIGMS NIH HHS
ID : R00 GM118885
Pays : United States
Déclaration de conflit d'intérêts
Conflict of Interest None.
Références
J Clin Invest. 2012 Dec;122(12):4727-31
pubmed: 23160196
Cytometry A. 2011 Jun;79(6):426-35
pubmed: 21548079
Stem Cells. 2012 Nov;30(11):2596-601
pubmed: 22948941
JVS Vasc Sci. 2021 May 15;2:136-148
pubmed: 34617064
Genetics. 1974 Mar;76(3):537-49
pubmed: 4833575
Stem Cell Res Ther. 2019 Dec 16;10(1):391
pubmed: 31843009
Circulation. 2015 Mar 17;131(11):1006-18
pubmed: 25593290
Nature. 2014 Oct 30;514(7524):585-90
pubmed: 25317562
JCI Insight. 2017 Feb 23;2(4):e91700
pubmed: 28239661
Circulation. 2014 Feb 11;129(6):692-703
pubmed: 24201301
Front Physiol. 2019 Oct 18;10:1311
pubmed: 31681017
Nature. 2020 Dec;588(7836):124-129
pubmed: 33268865
Physiol Rev. 2019 Apr 1;99(2):1281-1324
pubmed: 30864875
Am J Physiol. 1991 Jul;261(1 Pt 2):H83-7
pubmed: 1858934
Circulation. 2018 Oct 23;138(17):e484-e594
pubmed: 30354654
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
J Am Coll Cardiol. 2019 Jan 22;73(2):190-209
pubmed: 30654892
Mol Cancer. 2021 Jan 4;20(1):3
pubmed: 33397405
Nat Med. 2016 Jun;22(6):657-65
pubmed: 27183216
J Am Coll Cardiol. 2004 Oct 19;44(8):1636-40
pubmed: 15489096
Front Cell Dev Biol. 2022 Nov 08;10:1003028
pubmed: 36425528
Cell Rep. 2020 Dec 15;33(11):108491
pubmed: 33326796
Circ Res. 2022 May 27;130(11):1647-1659
pubmed: 35443807
J Am Heart Assoc. 2014 Jan 27;3(1):e000622
pubmed: 24470523
J Clin Invest. 2019 Jun 24;129(8):3121-3133
pubmed: 31232700
Biochem Soc Trans. 2011 Dec;39(6):1639-43
pubmed: 22103500
Sci Transl Med. 2014 Mar 12;6(227):227ra34
pubmed: 24622514
Am J Pathol. 1994 Feb;144(2):275-85
pubmed: 7508683
Circulation. 2023 Feb 21;147(8):e93-e621
pubmed: 36695182
Cardiovasc Res. 2022 Aug 24;118(11):2458-2477
pubmed: 35325071
Med Biol Eng Comput. 2008 May;46(5):461-7
pubmed: 18228071
Cell Rep. 2019 Nov 12;29(7):1986-2000.e8
pubmed: 31722212
Cardiovasc Res. 2015 Dec 1;108(3):377-86
pubmed: 26084310
Stem Cells. 2018 Dec;36(12):1851-1862
pubmed: 30270540
J Hypertens. 2001 May;19(5):921-30
pubmed: 11393676
Anat Rec A Discov Mol Cell Evol Biol. 2003 Oct;274(2):942-51
pubmed: 12973718
J Biol Chem. 2005 Mar 11;280(10):9719-27
pubmed: 15623517
News Physiol Sci. 2002 Jun;17:105-9
pubmed: 12021380
Circ Res. 2002 Jun 14;90(11):1189-96
pubmed: 12065322
Sci Rep. 2017 Jun 13;7(1):3375
pubmed: 28611395
J Cell Sci. 1992 Oct;103 ( Pt 2):521-9
pubmed: 1478952